TurnOnGreen Grants Stock Options to CEO Amos Kohn
TurnOnGreen, Inc. grants stock options to CEO Amos Kohn, enhancing leadership incentives and aligning with industry trends in executive compensation.
Moleculin Biotech CFO Reports Major Stock Transactions
Moleculin Biotech's CFO Jonathan P. Foster reports significant stock transactions, reflecting commitment to the company's growth in the pharmaceutical sector.
TurnOnGreen grants 9 million stock options to President Marcus
TurnOnGreen, Inc. grants 9 million stock options to President Charuvastra Marcus, enhancing executive compensation and aligning interests with shareholders.
CytomX CEO Corrects Stock Ownership in Recent SEC Filing
Sean A. McCarthy's SEC filing corrects stock ownership details, impacting CytomX Therapeutics and highlighting the importance of accurate reporting in the pharmaceutical sector.
Phillip D. Carrai Sells Shares in Kratos Defense & Security
Phillip D. Carrai, President of Kratos Defense, reported share sales as part of a trading plan, reflecting ongoing financial maneuvers in the defense sector.
FMC Corp CEO Brondeau Acquires 57 Shares of Common Stock
FMC Corp's CEO Pierre R. Brondeau acquires 57 shares, boosting his total holdings to 533,970 shares, signaling confidence in the company's future.
Junior Walner Alves Cunha Sells 33,679 Phantom Shares
Junior Walner Alves Cunha, VP at Suzano S.A., sells 33,679 performance phantom shares, reflecting executive compensation trends in the paper mills industry.
Johnson KLynne Increases Shareholding in FMC Corp
Johnson KLynne acquired 239 shares of FMC Corp, raising her total ownership to 44,774 shares, as detailed in the latest SEC filing.
FMC Corp director Kathy Fortmann acquires 130 shares
Kathy Fortmann of FMC Corp reports acquisition of 130 shares, emphasizing executive compensation in the chemicals industry.
Dominguez Joseph acquires 33 shares of KBR, Inc.
Dominguez Joseph reports acquisition of 33 shares in KBR, Inc., raising total holdings to 13,512 shares, reflecting ongoing investment activity.
Barry Michael F acquires shares in FMC Corp amid market changes
Barry Michael F reports acquisition of 15 shares in FMC Corp, boosting total holdings to 28,835.19 shares. Insider confidence in the chemicals sector.
FMC Corp director acquires shares in recent transaction
Carol Anthony Davidson, a director at FMC Corp, has acquired 107 shares, increasing her total ownership to 32,681 shares as of October 15, 2026.
ANI Pharmaceuticals CEO Nikhil Lalwani Sells 5,400 Shares
Nikhil Lalwani, CEO of ANI Pharmaceuticals, sold 5,400 shares of stock under a trading plan, reflecting ongoing stock management strategies.
Hassen Tyler Lewis buys 500,000 shares of Zone Frontier Inc.
Hassen Tyler Lewis purchases 500,000 shares of Zone Frontier Inc., signaling confidence in the company's future within the specialty cleaning industry.
Assumpcao Marcos Moreno Chagas Disposes of Phantom Shares
Assumpcao Marcos Moreno Chagas reports the disposal of 31,434 Performance Phantom Shares linked to Suzano S.A., reflecting ongoing executive compensation strategies.
Walter Schalka Disposes of 33,679 Performance Phantom Shares
Walter Schalka has disposed of 33,679 Performance Phantom Shares from Suzano S.A., reflecting changes in executive compensation strategies.
Suzano S.A. VP Sells 56,290 Phantom Shares in SEC Filing
Junior Carlos Anibal Fernandes de Almeida reports disposal of 56,290 phantom shares in Suzano S.A., reflecting industry trends in executive compensation.
Wang Lingke Reports Stock Transactions for Ethos Technologies
Wang Lingke discloses multiple stock transactions for Ethos Technologies, indicating strategic ownership adjustments. Details on future actions remain unclear.
PACS Group President Jergensen Sells 40,000 Shares
Joshua Jergensen, President and COO of PACS Group, sells 40,000 shares of common stock, retaining over 2.4 million shares.
James N. Wilson Reports Stock Sales in Corcept Therapeutics
James N. Wilson's recent stock transactions in Corcept Therapeutics may signal strategic financial moves, impacting investor sentiment in the pharmaceutical sector.